Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Lung Neoplasms 25Prostatic Neoplasms 23Carcinoma, Non-Small-Cell Lung 15Multiple Myeloma 14Sarcoma 12Leukemia, Myeloid, Acute 12Breast Neoplasms 12Lymphoma, Non-Hodgkin 10Glioma 10Wilms Tumor 9Colorectal Neoplasms 9Carcinoma, Hepatocellular 9Rectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Pancreatic Neoplasms 8Ovarian Neoplasms 8Osteosarcoma 8Neuroblastoma 8Neoplasm Metastasis 8Myelodysplastic Syndromes 8Rhabdomyosarcoma 7Rhabdoid Tumor 7Melanoma 7Medulloblastoma 7Hepatoblastoma 7Neuroectodermal Tumors, Primitive, Peripheral 6Mouth Neoplasms 6Lymphoma 6Histiocytosis, Langerhans-Cell 6Head and Neck Neoplasms 6

Interventions

enasidenib 1canakinumab 1X-Rays 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Clonal Cytopenia of Undetermined Significance × X-Rays × Clear all
NCT05641831 2026-01-02

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
110 enrolled
Classical hematology

Clonal Cytopenia of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡